New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
NCT ID NCT07342478
First seen Jan 16, 2026 · Last updated Jun 12, 2026 · Updated 17 times
Summary
This study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inhibitor. The goal is to see which drug works better at controlling the cancer for longer. About 306 adults will take one pill daily until their disease worsens or side effects become too much.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OSU Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
Optum Medical Group (Rhodes) P.C.
RECRUITINGLas Vegas, Nevada, 89102, United States
-
The Center for Cancer and Blood Disorders-Bethesda
RECRUITINGBethesda, Maryland, 20817, United States
-
UPMC Hillman Cancer Center
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.